Flexsteel Industries, Inc. Announces Quarterly Dividend
Get Alerts FLXS Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 1.1%
EPS Growth %: -18.3%
Join SI Premium – FREE
DUBUQUE, Iowa--(BUSINESS WIRE)-- Flexsteel Industries, Inc. (NASDAQ: FLXS) announced its Board of Directors declared a quarterly dividend of $0.25 per share, payable October 12, 2026, to shareholders of record as of September 30, 2026.
Flexsteel has paid cash dividends on its common stock each year since 1938. This is the 339th consecutive quarterly cash dividend.
About Flexsteel
Flexsteel Industries, Inc. and Subsidiaries (the “Company,” “Flexsteel,” or “Our”) is one of the largest residential furniture manufacturers, importers, and marketers in the U.S. Flexsteel addresses different consumer groups through our core brand, Flexsteel, and several category-specific sub-brands: Zecliner, Statements, Zen, Perfect Match, and Pulse, all of which have unique value propositions tailored to specific consumer needs. We offer a wide assortment of product solutions for different areas within the home including stationary and motion sofas, loveseats, chairs, and sectionals, as well as bedroom furniture, dining tables and chairs, occasional and entertainment tables, and kitchen storage. For more than 130 years, Flexsteel has strived to create strong consumer value with unmatched quality, comfort, and durability, backed by innovation and highlighted by its patented Blue Steel Spring technology, designed to deliver lasting comfort and support. Today, Flexsteel products are available nationwide through retail partners and online channels.
For more information, visit our website at http://www.flexsteel.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260915799638/en/
INVESTOR CONTACT:
Michael J. Ressler, Flexsteel Industries, Inc.
563-585-8116
[email protected]
Source: Flexsteel Industries, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
- Global Affairs Lab Releases Two Interactive Games on US-South Korea Economic Ties
- ITM and Lumara Bio Announce Real-World Re-treatment Data and Dosimetry Results from COMPETE for ¹⁷⁷Luedotreotide (ITM-11) in GEP-NETs at ASTRO 2026
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share